As-needed treatment with a β2-agonist or a β2-agonist/ corticosteroid combination in mild intermittent asthma (SOMA)

T. Haahtela, K. Tamminen, P. Malmberg, J. Karjalainen, H. Ylä-Outinen, O. Zetterström, T. Ekström, O. Selroos (Helsinki, Finland; , ; Linköping, Sweden)

Source: Annual Congress 2005 - Novel therapies for asthma
Session: Novel therapies for asthma
Session type: Poster Discussion
Number: 1722
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Haahtela, K. Tamminen, P. Malmberg, J. Karjalainen, H. Ylä-Outinen, O. Zetterström, T. Ekström, O. Selroos (Helsinki, Finland; , ; Linköping, Sweden). As-needed treatment with a β2-agonist or a β2-agonist/ corticosteroid combination in mild intermittent asthma (SOMA). Eur Respir J 2005; 26: Suppl. 49, 1722

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy
Source: Eur Respir J 2007; 30: Suppl. 51, 615s
Year: 2007

Adding slow-released theophyllne to inhaled corticosteroids in the treatment of mild persistent asthma
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007


Budesonide–formoterol reliever therapy in intermittent versus mild persistent asthma
Source: Eur Respir J, 57 (2) 2003064; 10.1183/13993003.03064-2020
Year: 2021



Comparison of the efficacy of cicleosonide with budesonide in mild to moderate asthma patients after step-down therapy
Source: Annual Congress 2011 - Asthma management and response
Year: 2011

Intermittent therapy with budesonide/formoterol in children with moderate asthma.
Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities
Year: 2017


Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2-agonists (LABA) in moderately severe COPD
Source: Annual Congress 2011 - Disease management in specific primary care populations
Year: 2011

Oral corticosteroids in the treatment of exacerbation of severe asthma
Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden
Year: 2020


The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 290s
Year: 2004

Rescue-free days in patients with mild persistent asthma receiving montelukast sodium or an inhaled corticosteroid
Source: Eur Respir J 2002; 20: Suppl. 38, 113s
Year: 2002

Nebulizer therapy with budesonide in addition to systemic corticosteroids in acute severe asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 541s
Year: 2004

Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007


Comparison of inhaled corticosteroid combined with theophylline and double-dose inhaled corticosteroid in moderate-severe persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 127s
Year: 2004

Novel combination inhaler for mild asthma treatment
Source: Annual Congress 2008 - Asthma control or asthma severity
Year: 2008


The response to combination therapy treatment regimens in severe/difficult-to-treat asthma
Source: Eur Respir J 2008; 32: 1237-1242
Year: 2008



The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA)
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012

Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017

Suboptimal persistence with inhaled corticosteroid (ICS) mono-therapy among children with persistent asthma in the UK
Source: Eur Respir J 2006; 28: Suppl. 50, 709s
Year: 2006

LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Year: 2015


Children with mild asthma: do they benefit from inhaled corticosteroids?
Source: Eur Respir J 2002; 20: 1470-1475
Year: 2002



Withdrawal of high-dose inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: a feasibility study in primary care.
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019